Competing interest
None
References
Aktoz M, Altay H, Aslanger E, Atalar E, Atar I, Aytekin V, et al.(2020). [Turkish Cardiology Association Consensus Report: COVID-19 Pandemic and Cardiovascular Diseases (May 13, 2020)]. Turk Kardiyol Dern Ars 48: 1-87.
Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, et al. (2020). QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin. Heart Rhythm.
Drici MD, & Clement N (2001). Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf 24: 575-585.
Gonin JM, Kadrofske MM, Schmaltz S, Bastyr EJ, 3rd, & Vinik AI (1990). Corrected Q-T interval prolongation as diagnostic tool for assessment of cardiac autonomic neuropathy in diabetes mellitus. Diabetes Care 13: 68-71.
Hancox JC, Hasnain M, Vieweg WV, Crouse EL, & Baranchuk A (2013). Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: A narrative review based on the study of case reports. Ther Adv Infect Dis 1: 155-165.
Helfenbein ED, Zhou SH, Lindauer JM, Field DQ, Gregg RE, Wang JJ, et al. (2006). An algorithm for continuous real-time QT interval monitoring. J Electrocardiol 39: S123-127.
Jankelson L, Karam G, Becker ML, Chinitz LA, & Tsai MC (2020). QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review. Heart Rhythm.
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. (2014). Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev: CD008965.
The cardiotoxicity of antimalarials. [Online] Available from https://www.who.int/malaria/mpac/mpac-mar2017-erg-cardiotoxicity-report-session2.pdf. [Accessed: 2017].
Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. (2020). Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol.
Ramireddy A, Chugh H, Reinier K, Ebinger J, Park E, Thompson M, et al. (2020). Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring. J Am Heart Assoc: e017144.
Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, et al. (2020). Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA.
Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, et al. (2020). The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol.
Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, et al.(2016). Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients. J Am Heart Assoc 5.
Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, et al. (2011). Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev 27: 639-653.
Tang C, Godfrey T, Stawell R, & Nikpour M (2012). Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J 42: 968-978.
Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. (2013). Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 6: 479-487.
Tripathy S, Dassarma B, Roy S, Chabalala H, & Matsabisa MG (2020). A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic. Int J Antimicrob Agents: 106028.
Wang C, Horby PW, Hayden FG, & Gao GF (2020). A novel coronavirus outbreak of global health concern. Lancet 395: 470-473.
Global surveillance for COVID-19 caused by human infection with COVID-19 virus. [Online] Available from https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov). [Accessed: April 20].
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. (2020). In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis.
Zengin R SZ, Karadağ N, Çuhadaroğlu Ç, Ergönül Ö, Kocagöz S. (2020). Adverse Cardiac Events Related to Hydroxychloroquine Prophylaxis and Treatment of COVID-19. Infect Dis Clin Microbiol 2: 24-26.
Ziegler D, Voss A, Rathmann W, Strom A, Perz S, Roden M, et al.(2015). Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey. Diabetologia 58: 1118-1128.